ArticleJACC. Advances2023
Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients.
Article in JACC. Advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Improved Anticoagulation Guideline Adherence and Clinical Outcome Through Hospital-Wide Atrial Fibrillation Alarming System.Acta Cardiologica Sinica · 2026Article
- Etiology and management of venous thromboembolism recurrence in patients anticoagulated for venous thromboembolism: a single-center study.Research and practice in thrombosis and haemostasis · 2026Article
- Sex and Racial Differences in Left Atrial Appendage Morphology.Journal of the American Heart Association · 2026Article
- Large Language Modeling-Enabled Analysis of Atrial Fibrillation on Social Media.Journal of the American Heart Association · 2026Article
- Medication Adherence Patterns for Patients with Atrial Fibrillation: A Mixed Methods Study to Understand Patient and Clinician Perspectives.Patient preference and adherence · 2026Article
- Impact of Social Determinants of Health on Primary Adherence of Oral Anticoagulants Among Patients with Newly Diagnosed Atrial Fibrillation.Cardiology and therapy · 2025Article
- Pharmacy-Led Management of Atrial Fibrillation: Improving Treatment Adherence and Patient Outcomes.Integrated pharmacy research & practice · 2024Review
- If a Thing Is Worth Doing, it Is Worth Doing Well.JACC. Advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonadherence to direct oral anticoagulants to prevent stroke occurs in up to 40% of atrial fibrillation patients. Underlying reasons are poorly understood. Objectives: This study quantified patient-reported reasons for nonadherence and identified strategies to improve adherence. Methods: This is a cross-sectional survey of atrial fibrillation patients in 2 academic health systems who reported apixaban nonadherence. We examined patient-reported reasons for nonadherence and level of nonadherence (assessed by a validated 3-item adherence measure) using a multivariable logistic regression model. Results: Of 419 study patients, 41.5% were women. The mean age was 71.1 ± 10 years and mean CHA Conclusions: Patients may not disclose their nonadherence to prescribers, and attitudes related to apixaban nonadherence differ among patients with mild nonadherence versus poor adherence. While all patients may benefit from strategies to address forgetfulness, concerns related to the purpose of apixaban, cost, and bleeding risk may require special attention in those with poor adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.